Introduction
Multiple myeloma (MM) is a clonal plasma-cell disorder. Multiple myeloma cells (MMC) from almost all patients harbor chromosomal abnormalities by FISH , and aberrant gene expression at diagnosis in symptomatic disease. These abnormalities are not 1 2 3 sufficient to promote MMC growth ex vivo and the tumor microenvironment expresses adhesion molecules and produces myeloma growth factors (MGF) that are critical to trigger MMC survival , . A plethora of MGF have been identified: interleukin-6 (IL-6) , soluble IL-6 4 5 6 receptor , the IL-6 family , insulin-like growth factor type 1 (IGF-1) , , BAFF/APRIL B cell growth factors , , the epidermal 7 8 9 10 11 12 growth factor (EGF) family , hepatocyte growth factor (HGF) , tumor necrosis factor (TNF) , the Wnt family , IL-10 , IL-21 13 14 15 16 17 , and the NOTCH ligand family . Some MGF can be produced by the tumor environment (IL-6, BAFF/APRIL, IGF-1, EGF family, 18 19 Wnt family, HGF) or by MMC themselves (IL-6, IGF-1, HGF, EGF family, Wnt family, Notch ligand family) , . These MGF activate 20 21 their specific receptors that in turn result in the activation of several signal transduction pathways including the Janus Kinase/signal 22 transducer and activator of transcription 3 (JAK/STAT3), PI-3 kinase/AKT, Ras/mitogen-activated protein kinase (MAPK), Nuclear Factor-kappa B (NF-B), and the -catenin pathway. In a minority of patients with extramedullary proliferation, MMC may grow without IGF-1 is the major growth factor on myeloma Blood. Author manuscript Page / 2 16 on different aspects, which could yield to challenging conclusions. Descamps . have reported that IGF-1 MGF activity was restricted et al to CD45 HMCLs, unlike the CD45 HMCLs . IL-6 could efficiently trigger the growth of CD45 HMCLs and the IL-6 activity was Another major question is the in vivo relevance of these MGF. Serum levels of IL-6 and soluble IL-6R and of IGF-1 were linked with bad prognosis , . Divergent data exist regarding the prognostic value of IGF-1R on MMC. With a small cohort of 37 newly-diagnosed 27 28 patients, Bataille . have shown that IGF-1R expression on MMC, detected by FACS analysis, had poor prognosis value . Using a et al 29 cohort of 72 newly-diagnosed patients and expression detected by Affymetrix microarray, Chng . failed to find a prognosis IGF-1R et al 30
value of expression, whereas expression was increased in poor prognosis groups. The prognostic value of the other MGF IGF-1R IGF-1R receptors was not documented yet.
To look for a possible ranking of five well-documented MGF, we used a defined serum-free culture medium able to sustain growth of all our HMCLs to avoid unidentified components present in serum, in particular IGF-1, which might confound interpretation of the results.
We also look for the prognostic value of MGF receptor gene expression on MMC using two independent large patient cohorts.
Materials and Methods

Cell samples
The 9 human myeloma cell lines (HMCLs) were obtained in our laboratory or purchased from ATCC (Rockville, MD, USA). They 31 were maintained in RPMI1640 (Gibco Invitrogen, France), 10 fetal bovine serum (FBS, PAA laboratory GmbH, Austria) and for the % IL-6-dependant cell lines, with 2 ng/ml of IL-6 (Abcys SA, Paris, France). Normal bone marrow plasma cells (BMPC) were obtained from healthy donors after informed consent was given. Plasma cells, CD27 memory B cells (MBC) and polyclonal plasmablasts (PPC, CD38 + + , CD20 ) were obtained as previously described .
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MMC of 171 patients with previously-untreated MM were included after written informed consent was given at the University hospitals of Heidelberg (Germany) or Montpellier (France). These 171 patients were treated with high dose therapy (HDC) and autologous stem cell transplantation (ASCT) and were termed in the following Heidelberg-Montpellier (HM) series. We also used Affymetrix data of a cohort of 345 purified MMC from previously-untreated patients from the Arkansas research group (Little Rock). The patients were treated with total therapy 2 and termed in the following LR-TT2 series. These data are publicly available (GEO, 33 , accession number GSE2658). http://www.ncbi.nlm.nih.gov/geo/
Reagents
Human recombinant (r) IL-6 (rIL-6), rIGF-1 and rHGF were purchased from Abcys SA (Paris, France), human rHB-EGF, rAPRIL, anti-human HGF monoclonal antibody (MoAb) and BCMA-Fc from R&D Systems (Minneapolis, MN). The B-E8 anti-IL6 MoAb was a generous gift from Dr Wijdenes (Diaclone, Besancon, France) , the NVP-AEW541 IGF-1R inhibitor from Novartis Pharma AG (Basel,  34 Switzerland) and PD169540 pan-ErbB kinase inhibitor from Pfizer Global Research and development (Ann Arbor, MI, USA). We used 35
Syn H, an Iscove-based fully-defined culture medium containing human albumin without insulin (ABCell-Bio, Montpellier, France).
Interphase FISH, microarray hybridization, Real-time RT-PCR
Interphase-FISH-analysis was performed according to our previously reported standard protocol . RNA was extracted and hybridized 2 to human Affymetrix microarrays as previously described . expression was evaluated by real-time RT-PCR using the 36 IGF-1R assays-on-demand primers and probes and the Man Universal Master Mix (Applied Biosystems, Courtaboeuf, France) as reported . Taq 36
Flow cytometry Analysis
The expression of CD45 isoforms and IGF-1R on HMCLs were evaluated by incubating 5 10 cells with PE-conjugated IGF-1 is the major growth factor on myeloma
Blood. Author manuscript Page / 3 16 HMCLs were IL-6-and serum-starved for 2 hours and cultured for 4 days in 96-well flat-bottomed microtiter plates in serum-free culture medium without cytokine (control) or with either rIL-6 (200 pg/mL), rIGF-1 (100 ng/mL), rHB-EGF (1 g/mL), rHGF (200 μ ng/mL), or rAPRIL (200 ng/mL), without or with the B-E8 anti-IL-6 MoAb (10 g/mL), the IGF-1R inhibitor NVP-AEW541 (1 M), the 
Measurement of cytokine concentration by ELISA
HMCLs were cultured for 2 days in Syn H serum-free culture medium without cytokine and IL-6 and IGF-1 in the culture supernatant were measured using ELISA kits with a detection level of 3 pg/ml and 45 pg/ml respectively (R&D, Minneapolis, MN). 
Spiked expression surrogating t(4;14) MMSET
MMSET . MMSET
Statistical analysis
A difference in the mean values of two (paired) groups was evaluated with a (paired) student test using the SPSS10 software. Gene t Expression Profiles were analyzed with our bioinformatics platform (RAGE, ) and with the Amazonia http://rage.montp.inserm.fr 38 website . The prognostic value of a probe set was evaluated combining Affymetrix data obtained with human genome U133 set or U133 39
Plus 2.0 microarrays. We used the Affymetrix call ( present or absent ) that is determined by the Affymetrix GCOS-software as indicator
whether a gene is expressed or not. When a probe set was absent in MMC of a fraction of patients ( and ), the survival of IGF-1R c-Met patients with MMC with a present or absent call was compared. When a probe set was present in MMC of all patients ( , , IL-6R gp130 , ), the survival of patients with a signal below or above the median signal was compared. The statistical significance of TACI BCMA differences in survival between groups of patients was calculated by the log-rank test. An event was defined as relapse or death (for EFS) or as death (for OAS). Multivariate analysis was performed using the Cox proportional hazards model. Survival curves were plotted using the Kaplan-Meier method.
Results
Autocrine IGF-1 is a critical survival factor of autonomously-surviving CD45 HMCLs in serum-free culture medium .05) ( ). A difference between autonomously and non-autonomously-surviving HMCL is CD45 expression. The 3 P ≤ Figure 1A autonomously-surviving HMCLs expressed the 3 CD45 isoforms either at a low level or not at all ( 6 , ) , and the 5 ≤ % Figure 1B non-autonomously-surviving HMCLs expressed at least two isoforms, mainly CD45RO and CD45RB. CD45RA HMCLs are less is found in 6/8 HMCLs, an IGF-1/IGF-1R loop in 7/8, an HGF/c-met loop in 2/8, BAFF-APRIL/BAFFR-BCMA-TACI loops in 3/8, and EGF family/ErbB family loops in 8/8 (results not shown). To investigate expression, we used the 203627_at probe set, which is IGF-1R the only one of 8 probe sets that correlated with expression assayed by RT-PCR (r .85, .002) and FACS analysis IGF-1R IGF-1R ). We also looked for the production of autocrine IGF-1 or Figure 2A IL-6. IL-6 could be detected in the culture supernatants of some cell lines (XG-1, XG-2 and XG-6) in agreement with previous reports . 40
IGF-1 protein was detected by western blot in the HMCLs that expressed gene by Affymetrix microarrays ( ), but IGF-1 IGF-1 Figure 2B concentration in HMCL culture supernatants was below Elisa detection limit ( 45 pg/ml). 
Expression of MGF-receptors
The expression of 6 genes coding for receptor complexes of 4 of the 5 MGF could be -IGF-1R, IL-6R, gp130, c-Met, TACI, BCMAevaluated with Affymetrix U133 2.0 Plus microarrays.
expressions are up-regulated throughout B cell to plasma IL-6R, gp130 and BCMA cell differentiation ( .05), unlike is not expressed in MBC, PPC, BMPC, but expressed in MMC in a fraction of the 123 P ≤ TACI. IGF-1R patients ( ). Figure 5 
Prognostic value of MGF-receptor expression
Among the 6 receptors, only (probe set 203627_at) and (probe set 205945_at) expression had prognostic value in the 2 IGF-1R IL-6R independent series of newly-diagnosed patients, the HM series of 171 patients and LR-TT2 series of 345 patients. The probe set IGF-1R had a present call in the MMC of 31 and 50 of patients in the HM and LR-TT2 series, respectively. , and were Table 1 Genetic abnormalities were assayed in 79 to 129 (depending on the abnormality) patients of the 171 HM patients series ( 
Discussion
We selected 5 documented MGF for which recombinant MGF and inhibitors are commercially available to define a hierarchy of their biological action on HMCLs. We have found that IGF-1 is the major MGF in agreement with several studies , , IL-6 an important one, 9 41 and that HGF, EGF family and BAFF/APRIL act on a subset of HMCLs only. In serum-free cultures, only the 3 CD45 HMCLs could of HGF or HB-EGF and also by the IGF-1R inhibitor, but not the anti-IL-6 MoAb, BCMA-FC and pan-ErbB kinase inhibitor (for HGF effect) or anti-HGF MoAb (for HB-EGF effect). Thus targeting IGF-1R could also help to block their activity. Only APRIL-activity is not affected by IGF-1R inhibition. Out of the 3 BAFF/APRIL receptors --MMC expressed always , in BAFF-R, TACI, BCMA BCMA TACI 
IGF-1R
be evaluated in patients treated with anti-IGF-1 therapy. Anti-IL-6 MoAb treatment was also shown to block MMC proliferation with temporary disease stabilization . Thus, anti-IL-6 therapy could be a useful combination with an IGF-1 inhibitor. 51
In conclusion, this study makes it possible to define a hierarchy of the biological action of 5 well-documented MGF on HMCLs, IGF-1 being the major one, IL-6 an important one, and HGF, EGF family and BAFF/APRIL acting only on a subset of HMCLs. Of interest, this hierarchy of biological activity of these 5 MGF using HMCLs fully paralleled with the prognostic value of the expression of the genes of the receptors of these MGF in MMC since and expressions in MMC had prognostic value. Thus, gene expression profiles of IGF-1R IL-6R
MMC and of the tumor environment is highly recommended for a better understanding and anticipation of the efficacy of growth factor targeted therapy in patients with MM.
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Event-free survival and overall survival of patients with previously- 
